Role of hepatic intra-arterial therapies in metastatic neuroendocrine tumours (NET): Guidelines from the NET-Liver-Metastases Consensus Conference

HPB

Volumn 17, Issue 1, 2015, Pages 29-37

  Kennedy, Andrew ^a   Bester, Lourens ^b   Salem, Riad ^c   Sharma, Ricky A ^d   Parks, Rowan W ^e   Ruszniewski, Philippe ^f  

^a SARAH CANNON RESEARCH INSTITUTE   (United States)

^b ST VINCENT S HOSPITAL   (Australia)

^c NORTHWESTERN UNIVERSITY   (United States)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e UNIVERSITY OF EDINBURGH   (United Kingdom)

^f BEAUJON HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; FLUOROURACIL; GEMCITABINE; MITOMYCIN; YTTRIUM 90; RADIOPHARMACEUTICAL AGENT;

ARTICLE; ARTIFICIAL EMBOLISM; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CHEMOEMBOLIZATION; CONSENSUS; HUMAN; INTERMETHOD COMPARISON; LIVER METASTASIS; MOLECULARLY TARGETED THERAPY; NATIONAL HEALTH ORGANIZATION; NEUROENDOCRINE TUMOR; OVERALL SURVIVAL; PEER REVIEW; PRACTICE GUIDELINE; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RADIOEMBOLIZATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMIC THERAPY; TREATMENT RESPONSE; ADVERSE EFFECTS; CONSENSUS DEVELOPMENT; HEPATIC ARTERY; LIVER NEOPLASMS; MORTALITY; NEUROENDOCRINE TUMORS; PATIENT SELECTION; PROCEDURES; RISK ASSESSMENT; RISK FACTOR; SECONDARY; STANDARDS; TIME; TREATMENT OUTCOME;

CHEMOEMBOLIZATION, THERAPEUTIC; EMBOLIZATION, THERAPEUTIC; HEPATIC ARTERY; HUMANS; LIVER NEOPLASMS; NEUROENDOCRINE TUMORS; PATIENT SELECTION; RADIOPHARMACEUTICALS; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84916201566     PISSN: 1365182X     EISSN: 14772574     Source Type: Journal    
DOI: 10.1111/hpb.12326     Document Type: Article

References (34)

1. Pavel M, Baudin E, Couvelard A, Krenning E, Oberg K, Steinmuller T, et al. (2012) ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 95: 157-176.
2. Frilling A, Modlin IM, Kidd M, Russell C, Breitenstein S, Salem R, et al. (2014) Recommendations for management of patients with neuroendocrine liver metastases. Lancet Oncol 15: e8-21.
3. Yang TX, Chua TC, Morris DL,. (2012) Radioembolization and chemoembolization for unresectable neuroendocrine liver metastases-a systematic review. Surg Oncol 21: 299-308.
4. National Cancer Institute. PDQ Levels of Evidence for Adult and Pediatric Cancer Treatment Studies. 2012. Available at http://cancer.gov/cancertopics/pdq/levels-evidence-adult-treatment/HealthProfessional (last accessed 1 June 2014).
5. Guyatt GH, Oxman AD, Kunz R, Falck-Ytter Y, Vist GE, Liberati A, et al. (2008) Going from evidence to recommendations. BMJ 336: 1049-1051.
6. de Baere T, Deschamps F, Teriitheau C, Rao P, Conengrapht K, Schlumberger M, et al. (2008) Transarterial chemoembolization of liver metastases from well differentiated gastroenteropancreatic endocrine tumours with doxorubicin-eluting beads: preliminary results. J Vasc Interv Radiol 19: 855-861.
7. Dong XD, Carr BI,. (2011) Hepatic artery chemoembolization for the treatment of liver metastases from neuroendocrine tumours: a longterm follow-up in 123 patients. Med Oncol 28 (Suppl. 1): 286-290.
8. Eriksson BK, Larsson EG, Skogseid BM, Lofberg AM, Lorelius LE, Oberg KE,. (1998) Liver embolizations of patients with malignant neuroendocrine gastrointestinal tumours. Cancer 83: 2293-2301.
9. Guiu B, Deschamps F, Aho S, Munck F, Dromain C, Boige V, et al. (2012) Liver/biliary injuries following chemoembolization of endocrine tumours and hepatocellular carcinoma: lipiodol vs. drug-eluting beads. J Hepatol 56: 609-617.
10. Gupta S, Johnson MM, Murthy R, Ahrar K, Wallace MJ, Madoff DC, et al. (2005) Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumours: variables affecting response rates and survival. Cancer 104: 1590-1602.
11. Loewe C, Schindl M, Cejna M, Niederle B, Lammer J, Thurnher S,. (2003) Permanent transarterial embolization of neuroendocrine metastases of the liver using cyanoacrylate and lipiodol: assessment of mid- and longterm results. AJR Am J Roentgenol 180: 1379-1384.
12. Maire F, Lombard-Bohas C, O'Toole D, Vullierme MP, Rebours V, Couvelard A, et al. (2012) Hepatic arterial embolization versus chemoembolization in the treatment of liver metastases from well-differentiated midgut endocrine tumours: a prospective randomized study. Neuroendocrinology 96: 294-300.
13. Pitt SC, Knuth J, Keily JM, McDermott JC, Weber SM, Chen H, et al. (2008) Hepatic neuroendocrine metastases: chemo- or bland embolization? J Gastrointest Surg 12: 1951-1960.
14. Ruszniewski P, Rougier P, Roche A, Legmann P, Sibert A, Hochlaf S, et al. (1993) Hepatic arterial chemoembolization in patients with liver metastases of endocrine tumours. A prospective phase II study in 24 patients. Cancer 71: 2624-2630.
15. Ruutiainen AT, Soulen MC, Tuite CM, Clark TW, Mondschein JI, Stavropoulos SW, et al. (2007) Chemoembolization and bland embolization of neuroendocrine tumour metastases to the liver. J Vasc Interv Radiol 18: 847-855.
16. Vogl TJ, Gruber T, Naguib NN, Hammerstingl R, Nour-Eldin NE,. (2009) Liver metastases of neuroendocrine tumours: treatment with hepatic transarterial chemotherapy using two therapeutic protocols. AJR Am J Roentgenol 193: 941-947.
17. Cao CQ, Yan TD, Bester L, Liauw W, Morris DL,. (2010) Radioembolization with yttrium microspheres for neuroendocrine tumour liver metastases. Br J Surg 97: 537-543.
18. 90Y-microspheres: early results in 148 patients. Am J Clin Oncol 31: 271-279.
19. King J, Quinn R, Glenn DM, Janssen J, Tong D, Liaw W, et al. (2008) Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases. Cancer 113: 921-929.
20. Memon K, Lewandowski RJ, Mulcahy MF, Riaz A, Ryu RK, Sato KT, et al. (2012) Radioembolization for neuroendocrine liver metastases: safety, imaging, and longterm outcomes. Int J Radiat Oncol Biol Phys 83: 887-894.
21. Paprottka PM, Hoffmann RT, Haug A, Sommer WH, Raessler F, Trumm CG, et al. (2012) Radioembolization of symptomatic, unresectable neuroendocrine hepatic metastases using yttrium-90 microspheres. Cardiovasc Intervent Radiol 35: 334-342.
22. 90Y Radioembolization for metastatic neuroendocrine liver tumours: preliminary results from a multi-institutional experience. Ann Surg 247: 1029-1035.
23. Saxena A, Chua TC, Bester L, Kokandi A, Morris DL,. (2010) Factors predicting response and survival after yttrium-90 radioembolization of unresectable neuroendocrine tumour liver metastases: a critical appraisal of 48 cases. Ann Surg 251: 910-916.
24. Kalinowski M, Dressler M, Konig A, El-Sheik M, Rinke A, Hoffken H, et al. (2009) Selective internal radiotherapy with yttrium-90 microspheres for hepatic metastatic neuroendocrine tumours: a prospective single centre study. Digestion 79: 137-142.
25. Frilling A, Li J, Malamutmann E, Schmid KW, Bockisch A, Broelsch CE,. (2009) Treatment of liver metastases from neuroendocrine tumours in relation to the extent of hepatic disease. Br J Surg 96: 175-184.
26. Sarmiento JM, Que FG,. (2003) Hepatic surgery for metastases from neuroendocrine tumours. Surg Oncol Clin N Am 12: 231-242.
27. Berber E, Flesher N, Siperstein AE,. (2002) Laparoscopic radiofrequency ablation of neuroendocrine liver metastases. World J Surg 26: 985-990.
28. Eriksson J, Stalberg P, Nilsson A, Krause J, Lundberg C, Skogseid B, et al. (2008) Surgery and radiofrequency ablation for treatment of liver metastases from midgut and foregut carcinoids and endocrine pancreatic tumours. World J Surg 32: 930-938.
29. Vogl TJ, Naguib NN, Zangos S, Eichler K, Hedayati A, Nour-Eldin NE,. (2009) Liver metastases of neuroendocrine carcinomas: interventional treatment via transarterial embolization, chemoembolization and thermal ablation. Eur J Radiol 72: 517-528.
30. Wang LM, Jani AR, Hill EJ, Sharma RA,. (2013) Anatomical basis and histopathological changes resulting from selective internal radiotherapy for liver metastases. J Clin Pathol 66: 205-211.
31. Roche A, Girish BV, de Baere T, Baudin E, Boige V, Elias D, et al. (2003) Trans-catheter arterial chemoembolization as first-line treatment for hepatic metastases from endocrine tumours. Eur Radiol 13: 136-140.
32. Dutton S, Kenealy N, Love S, Wasan H, Sharma R, Group FP, et al. (2014) Study protocol: FOXFIRE: an open-label, randomized, phase III trial of 5-fluorouracil, oxaliplatin and folinic acid (OxMdG) with or without interventional selective internal radiation therapy (SIRT) as first-line treatment for patients with unresectable liver-only or liver-dominant metastatic colorectal cancer. BMC Cancer 14: 497.
33. 3]octreotate. J Nucl Med 52: 1361-1368.
34. Yadegarfar G, Friend L, Jones L, Plum LM, Ardill J, Taal B, et al. (2013) Validation of the EORTC QLQ-GINET21 questionnaire for assessing quality of life of patients with gastrointestinal neuroendocrine tumours. Br J Cancer 108: 301-310.